



MOHAMED NOUR EL-DIEN

Ass. Prof. of OB/GYN – S.F.M. – 2022

• Incidence:

A- 1ry Of all genital cancer: 1.5-3%

B- 2ry: more common

• *Site:* -Upper 1/3: 55% -Middle 1/3: 15%

-Lower 1/3: 30%

Age:

- < 2Ys.: Endodermal sinus tumor
- *2-7Ys.:* -Sarcoma
- 7-35Ys.: DES-induced adenocarcinoma
- 35-70Ys.:-Squamous cell Carcinoma
- Post menopause:
 - -mesonephric& endometriotic adenocarcinoma
 - -Melanoma: 0.5 %

- *Etiology:* (Risk Factors):
- > Squamous cell carcinoma:
 - 1- chronic irritation
 - 2- possible carcinogens of cancer cervix

> Clear cell adenocarcinoma:

- -Genetic predisposition.
- -IU exposure to DES < 18 weeks.
- -viral modulation

Histopathological classification:

<u>A- 1ry:</u>

- Squamous cell Carcinoma
- Adeno carcinoma:
 - Clear cell (DES-induced)
 - Mesonephric
 - Endometriotic
- Melanoma: 0.5 %
- Endodermal sinus tumor
- Sarcoma:
 - Spindle-cell (lieo-myo-fibro) sarcoma
 - Sarcoma botryoids (rhabdo-myo, grape-like) sarcoma.


B- 2ry:

- more common; Origins:
- a) Genital: cervix, vulva, endometrium, ovary, tube, GTT.
- b) Extra-genital: urinary (bladder, urethra), GIT (rectum).

- Gross picture:
- Ulcerative.



cauliflower



• Spread:

• Direct:-

- -Anterior:-bladder & uretha
- -Posterior:-rectum
- -Upwards:-cervix
- -Downwards:-vulva
- -Lateral:-Paracolpium.

• Lymphatics:-

- Upper 1/3: as cervix
- Middle 1/3:variable
- Lower 1/3: as vulva

• Vascular:

-usually late even in sarcoma



• Diagnosis:

	Squamous cell carcinoma	Clear cell adenocarcinoma
Onset	Delayed	Early
Age	Delayed	Young
Sexual activity	Inactive	Active

• Clinical picture:

- > Symptoms:
- -Bleeding. -Discharge.
- -Urinary symptoms. -Mass.
- > Signs:
- Bleeding
- Vagina:
 - Site (anterior, posterior) (upper, middle, lower 1/3)
 - Gross lesion (Ulcerative, Cauliflower mass)
 - infiltration to the underlying tissues
 - Extension to the surroundings (paracolpos, cervix, vulva)

• PR:

- -rectal mucosa.
- -Inguinal region: -affection, number, Site, size, fixity (underlying, covering), consistency.
- -Bimanual: pelvic nodes


> Investigations:

- for Confirmation: (Representative Biopsy)
 - Diagnosis:-confirmation -type (pathological)
 - Prognosis:-depth -grade -vessel invasion
- for Spread:
 - Local:-cystoscope -clposcope -proctoscope
 - Regional: lymphangiography, barium enema
 - Distant: imaging (chest X-ray, IVU, CT, MRI)
- for Preoperative physical fitness.

- **Staging** (Clinical: current):
- > Absolute requirements:
- -Clinical: thorough history good examination
- -Imaging: -chest X-ray, -IVU
- -Endoscopies:-cystoscope -proctoscope

> FIGO Staging:

Stage 0	Carcinoma <i>in situ</i> , intraepithelia carcinoma.
Stage I	The carcinoma is limited to the vaginal wall.
Stage II	The carcinoma has involved the subvaginal tissue but has not extended to the pelvic wall.
Stage III	The carcinoma has extended to the pelvic wall.
Stage IV	The carcinoma has extended beyond the true pelvis or has involved the mucosa of the bladder or rectum.
Stage IVa	Spread of the growth to adjacent organs.
Stage IVb	Spread to distant organs.



Treatment:

depends on the type:

I- <u>Squamous cell carcinoma</u>: Radiotherapy mainly
If hysterectomy was previously done: Open Implant to protect
the viscera

0	Local excision		
	<2.5mm: local excision		
I	2.5-5mm: Interstitial irradiation		
≤2 cm	>5mm: Interstitial+ Intracavitary irradiation		
> 2cm	External whole pelvis+ Interstitial+ Intracavitary		

II- <u>Clear cell adenocarcinoma</u>: Radiotherapy = Surgery

Stage	Surgery	Radiotherapy
l ≤ 2cm	Local excision + pelvic lymphadenectomy	NO
I > 2 cm	Radical Colpo-hysterectomy	Whole pelvis Or
II, III, IV	Pelvic exenteration	interstitial 5000 r

III-Melanoma:

Upper 2/3: Pelvic Exenteration

Lower 1/3: radical vulvo -colpectomy

IV - Endodermal sinus tumor

Surgery + Chemotherapy

V -Sarcoma:-

Local excision + Chemotherapy

